Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - methylphenidate hydrochloride 18mg (tablet core 13.5mg, immediate release sub-coat 4.5mg);   - modified release tablet - 18 mg - active: methylphenidate hydrochloride 18mg (tablet core 13.5mg, immediate release sub-coat 4.5mg)   excipient: acetone colloidal silicon dioxide fumaric acid hypromellose   opadry yellow ii 85f220137 isopropyl alcohol lactose monohydrate magnesium stearate methacrylic acid copolymer opacode black s-1-17823 purified talc purified water triethyl citrate - methylphenidate extended release (teva) is indicated for the treatment of attention deficit hyperactivity disorder (adhd)

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - methylphenidate hydrochloride 27mg (tablet core = 20.25mg, immediate release sub-coat = 6.75mg);   - modified release tablet - 27 mg - active: methylphenidate hydrochloride 27mg (tablet core = 20.25mg, immediate release sub-coat = 6.75mg)   excipient: acetone colloidal silicon dioxide fumaric acid hypromellose   opadry grey ii 85f275019 isopropyl alcohol lactose monohydrate magnesium stearate methacrylic acid copolymer opacode black s-1-17823 purified talc purified water triethyl citrate - methylphenidate extended release (teva) is indicated for the treatment of attention deficit hyperactivity disorder (adhd)

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - methylphenidate hydrochloride 36mg (tablet core = 27mg, immediate release sub-coat = 9mg);   - modified release tablet - 36 mg - active: methylphenidate hydrochloride 36mg (tablet core = 27mg, immediate release sub-coat = 9mg)   excipient: acetone colloidal silicon dioxide fumaric acid hypromellose   opadry white ii 85f48105 isopropyl alcohol lactose monohydrate magnesium stearate methacrylic acid copolymer opacode black s-1-17823 purified talc purified water triethyl citrate - methylphenidate extended release (teva) is indicated for the treatment of attention deficit hyperactivity disorder (adhd)

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - methylphenidate hydrochloride 54mg (tablet core = 40.5mg, immediate release coat = 13.5mg);   - modified release tablet - 54 mg - active: methylphenidate hydrochloride 54mg (tablet core = 40.5mg, immediate release coat = 13.5mg)   excipient: acetone colloidal silicon dioxide fumaric acid hypromellose   opadry red ii 85f15266 isopropyl alcohol lactose monohydrate magnesium stearate methacrylic acid copolymer opacode black s-1-17823 purified talc purified water triethyl citrate - methylphenidate extended release (teva) is indicated for the treatment of attention deficit hyperactivity disorder (adhd)

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - amitriptyline hydrochloride 10mg;  ;  ;  ; amitriptyline hydrochloride 10mg - film coated tablet - 10 mg - active: amitriptyline hydrochloride 10mg       excipient: colloidal silicon dioxide crospovidone hypromellose indigo carmine aluminium lake lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc   titanium dioxide active: amitriptyline hydrochloride 10mg excipient: brilliant blue fcf colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc   titanium dioxide - for the treatment of depression.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - amitriptyline hydrochloride 50mg;  ;  ;  ; amitriptyline hydrochloride 50mg - film coated tablet - 50 mg - active: amitriptyline hydrochloride 50mg       excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide red lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc   quinoline yellow titanium dioxide active: amitriptyline hydrochloride 50mg excipient: colloidal silicon dioxide crospovidone hypromellose indigo carmine aluminium lake lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc   sunset yellow fcf titanium dioxide - for the treatment of depression.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - hydrochlorothiazide 12.5mg; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified talc purified water   quinoline yellow starch titanium dioxide - for the treatment of hypertension, for patients in whom combination therapy is appropriate

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - latanoprost 0.05 mg/ml - eye drops, solution - 50 mcg/ml - active: latanoprost 0.05 mg/ml excipient: benzalkonium chloride dibasic sodium phosphate monobasic sodium phosphate monohydrate sodium chloride water for injection - indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 100mg; lamotrigine 100mg - chewable/dispersible tablet - 100 mg - active: lamotrigine 100mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium active: lamotrigine 100mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 200mg - chewable/dispersible tablet - 200 mg - active: lamotrigine 200mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.